The FDA is broadening what Eli Lilly’s Mounjaro can be used to treat. (Source: Eli Lilly and Company)

The FDA is broadening what Eli Lilly’s Mounjaro can be used to treat. (Source: Eli Lilly and Company)

The FDA is broadening what Eli Lilly’s Mounjaro can be used to treat. (Source: Eli Lilly and Company)

Hanmi Pharmaceutical signed two technology transfer agreements worth up to 5.0865 trillion won (approximately $3.7 billion) with Genentech and Eli…

Eli Lilly is the leader in the GLP-1 space, but the company can't rest on its laurels.

Eli Lilly es el líder en el espacio GLP-1, pero la empresa puede

Novo Nordisk se está inclinando hacia la conveniencia mientras intenta recuperar su liderazgo en el espacio de pérdida de peso GLP-1.

BioArctic and Eli Lilly (NYSE: LLY) announced a research collaboration to develop a new Alzheimer's treatment that combines BioArctic's BrainTransporter technology with an Eli Lilly drug candidate. The agreement focuses on improving delivery of Alzheimer’s therapies to the brain and expands Eli Lilly's neurology partnership efforts. The collaboration adds another project to Eli Lilly's neurodegenerative disease pipeline, an area that remains a key focus for large pharmaceutical...

Eli Lilly (NYSE: LLY) received FDA approval for Mounjaro to reduce major cardiovascular risk in adults with type 2 diabetes who are at high risk. The new indication expands Mounjaro’s approved use beyond blood sugar control to include cardiovascular risk reduction. The decision could influence how clinicians position Mounjaro in care plans for adults with type 2 diabetes and elevated cardiovascular risk. Payers may factor the cardiovascular indication into future coverage and reimbursement...

On August 17, OmniAb, Inc. (NASDAQ:OABI) announced a global collaboration and license agreement with Eli Lilly and Company (NYSE:LLY) to discover and develop novel ion channel therapeutics. Leveraging OmniAb’s specialized antibody discovery platform, the deal grants Lilly exclusive global rights to commercialize resulting candidates in exchange for an upfront payment, up to $370 million in […]

The new indication for Eli Lilly's drug is for people with Type 2 diabetes.

The FDA has approved Eli Lilly's Mounjaro to reduce the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes and…

Mounjaro has racked up sales of more than $55 billion since hitting the market, including $18.6 billion in the first half of 2026.

Eli Lilly receives FDA approval allowing Mounjaro to reduce major cardiovascular event risk in adults with type 2 diabetes at high risk.

With the approval, Eli Lilly’s Mounjaro becomes the first dual GIP/GLP-1 receptor agonist indicated to lower the risk of heart attack, stroke or cardiovascular death in adults with type 2 diabetes.